|Bid||0.3400 x N/A|
|Ask||0.3500 x N/A|
|Day's range||0.3350 - 0.3400|
|52-week range||0.1350 - 0.4500|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.52|
BRISBANE, Australia, February 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba"), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.
BRISBANE, Australia, November 29, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) ("Sonic") has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Micr
BRISBANE, Australia, October 27, 2022--SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.